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Chronic intractable heart failure that is unresponsive to maximum medical therapy can have 
a wide variety of causes; these include advanced valvular diseases and severe myocardial 
ischemia, ischemic cardiomyopathy (ICM) in heart failure following extensive myocardial 
infarction, chronic heart failure due to dilated cardiomyopathy (DCM) in which the myo-
cardium itself is progressively damaged or the acute aggravation of the latter. Heart trans-
plantation has long been considered the only useful treatment for patients with heart failure 
due to ICM- and DCM-induced severe left ventricular hypofunction. However, because of 
the extremely limited number of heart transplant donors, other surgical treatments have 
also been attempted. In this communication, we provide an overview of the current situation 
with regard to left ventriculoplasty and heart transplantations, as well as of the treatment of 
severe heart failure using ventricular assist devices, which have recently shown remarkable 
progress.
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Chronic intractable heart failure that is unrespon-
sive to maximum medical therapy can have a wide 
variety of causes. These include advanced valvular 
diseases; severe myocardial ischemia; ischemic 
cardiomyopathy (ICM), which is a state of chronic 
heart failure that develops after an extensive myo-
cardial infarction; and dilated cardiomyopathy 
(DCM), which is heart failure due to the failure of 
myocardial cells. Heart transplant has long been 
considered the only treatment for patients with 
heart failure due to severe left ventricular functional 
decline resulting from ICM and DCM. However, 
because of the very limited number of heart trans-
plant donors, other surgical treatments have also 
been attempted. Left ventriculoplasty is one such 
treatment that involves adjusting the shape, reduc-
ing the volume, and improving the function of the 
left ventricle, whose lumen is enlarged because of 
heart failure. It has been clinically applied for the 
treatment of ICM since the 1980s (Dor et al., 1995), 
and its indication has also spread to the treatment 
of DCM since the 1990s (Batista et al., 1996). How-
ever, the limitations of these surgical procedures 
have been gradually revealed in recent years, and 
continual efforts have been made to improve surgi-
cal methods and to establish their indications (Suma 
and RESTORE Group, 2001; Matsui et al., 2004).
 Since the establishment of the Organ Trans-
plant Law in 1997, heart transplantation from brain-
dead patients has also been performed in Japan. 
However, the law strictly required that in order for 
organs to be transplanted, the donors had to express 
their intent to donate their organs when alive; con-
sequently, 10 years since the enforcement of the law, 
50
M. Nishimura
mural myocardial infarction was first performed 
by Cooley in 1958 under artificial heart and lung 
support; many later studies have shown its effective-
ness. Dor et al. reported, beginning in the 1980s, 
that even in treatment of ICM (which causes an 
overall decrease in left ventricular function because 
of extensive akinesis), left ventriculoplasty was also 
believed to improve cardiac function, in the same 
manner as in its use in the treatment of left ven-
tricular aneurysms (Dor et al., 1995). Because of the 
spread of early intervention in the treatment of acute 
myocardial infarction, the number of patients with 
persistent akinesis due to subendocardial infarc-
tions tends to be higher than that due to transmural 
infarctions. However, after a relatively extensive 
myocardial infarction, and regardless of whether 
the infarcted region shows dyskinesis or akinesis, a 
remodeling occurs, causing a gradual expansion of 
the noninfarcted region along with deterioration in 
its function. Ultimately, this leads to ICM, namely, 
a decrease in the contractility of the entire left ven-
tricle. In such cases, left ventriculoplasty is applied 
that aims to improve both the contractility of the re-
maining noninfarcted region and the left ventricular 
dilatation and morphological changes caused by the 
remodeling during surgical resection or plasty of 
the infarcted region.
 
Surgical procedure 
 
The problem with the conventional surgical tech-
nique (a method known as “linear closure”, which 
consists of performing a longitudinal incision in 
the infarcted region in the anterior wall of the left 
ventricle, with resection and suturing of the in-
farcted area) is that the infarcted region remains in 
the septum; therefore, Dor et al. proposed a method 
consisting of a purse-string suture (a Fontan stitch) 
at the infarction site, including the septum and 
its border with healthy areas, followed by closure 
through application of a patch (Dor et al., 1995). 
Ever since its introduction, the method has been 
widely used worldwide. In addition, the surgical 
technique known as septal anterior ventricular ex-
clusion (SAVE), in which a vertical patch is sewn at 
the number of brain-dead donors has been approxi-
mately 60, which, in a population of 100 million 
people, was the equivalent of 5 brain-dead donors 
per year, in other words, 100 times less than the 
number found in Western countries. Under such cir-
cumstances, the revised version of the Organ Trans-
plant Law was enacted in 2010, and organ donation 
from a brain-dead patient has become possible upon 
obtaining consent from the patient’s family mem-
bers, even in the absence of a declaration of inten-
tion provided by the patient before death. Therefore, 
the number of heart transplants performed has in-
creased to 50 per year. However, the number is still 
only about one-tenth of that in Western countries 
and thus is still insufficient. In the 1990s, left ven-
tricular assist devices (LVADs) were actively used 
as a bridge in heart transplantation. In particular, 
implantable LVADs such as HeartMate (Thoratec, 
Pleasanton, CA) and Novacor (WorldHeart, Ottawa, 
Canada) have been widely used in Europe and the 
United States because of their capability to provide 
a better long-term quality of life (QOL). The practi-
cal use of small-sized and long-term durable contin-
uous-flow pumps in clinical settings was initiated 
in 2000. Therefore, the survival rate has improved, 
and destination therapy has been attempted on pa-
tients who are not candidates for heart transplanta-
tion. In addition, there have been reported cases in 
which the patients’ own cardiac function recovered 
after using VADs for circulatory support, which en-
abled these patients to withdraw from these VADs 
(bridge to recovery); this has attracted attention as a 
new possibility (Müller et al., 1997).
 The present report provides an overview of the 
current situation regarding the surgical treatment of 
severe heart failure.
 
Left ventriculoplasty for 
the treatment of ischemic cardiomyopathy
 
Concept
 
Resection of left ventricular aneurysms to treat the 
extensive dyskinesis that can occur after a trans-
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the border between the infarcted area and healthy 
regions, has also been performed. In this technique, 
Fontan stitch is not required to ensure that the left 
ventricle has a shortened transverse diameter and an 
oblong shape (Suma and RESTORE Group, 2001). 
Both methods allow for a reduction in the volume of 
the left ventricle and make it possible to ensure that 
the morphology of the left ventricle (which becomes 
spherical due to remodeling) returns to its original 
oblong shape.
Indications and outcomes
 
The indications for this surgical technique include 
the presence of symptoms such as heart failure, 
chest pain, and arrhythmia; akinesis or dyskinesis 
over a broad region (occupying 35% or more of the 
left ventricular circumference) due to anteroseptal 
myocardial infarction; and expansion of the left 
ventricle (left ventricular end-diastolic volume in-
dex greater than 100 mL/m2 or left ventricular end-
systolic volume index greater than 60 mL/m2) and 
a decrease in left ventricular contractility (Meni-
canti et al. and RESTORE Group, 2002). Recently 
reported studies conducted in other facilities have 
shown that left ventriculoplasty has comparatively 
favorable outcomes. Surgical patients who met the 
above-mentioned indications have been reported to 
account for 1,198 cases, with a hospital mortality 
rate of 5.3%, a 5-year survival rate of 68.6%, and 
a 78% avoidance of heart failure at 5 years after 
surgery (Athanasuleas et al. and RESTORE Group, 
2004). In addition, the efficacy of left ventriculo-
plasty in the treatment of mitral regurgitation (MR) 
has recently been the focus of attention. In ICM, 
which is often associated with left ventricular en-
largement, annuloectasia and tethering of the mitral 
valve leaflets due to displacement of the papillary 
muscle cause reduction in the coaptation area and is 
often complicated by MR. Commonly, “undersizing 
and overcorrecting” by employing small-diameter 
full-circumference prosthetic valves enables restora-
tion of the coaptation areas of the mitral valve leaf-
lets and an improvement in MR. However, residual 
MR and recurrences often occur in patients with 
severe tethering. During left ventriculoplasty, if su-
tures are also placed between the anterior and pos-
terior papillary muscles for shortening the distance 
and restoring the mitral tethering from inside the 
left ventricle, the treatment was found to be more 
physiological and recurrences may be prevented 
(Menicanti et al. and RESTORE Group, 2004). 
Further, it has also been reported that in patients 
with a history of severe ventricular arrhythmias, the 
incidence can be reduced by cryocoagulation of the 
“gray zone” located at the borderline between the 
infarcted and noninfarcted regions, and the results 
comparable to those obtained using automated im-
plantable cardioverter-defibrillators (DiDonato et al. 
and RESTORE Group, 2004).
 
 
Left ventriculoplasty
for the treatment of idiopathic DCM
 
Batista surgery
 
In treatment of DCM, Batista first reported im-
provement in left ventricular contractility by reduc-
ing the left ventricular volume by performing a 
partial resection of the posterior wall of the left ven-
tricle (Batista et al., 1996). Since then, the method 
has rapidly spread worldwide as “Batista’s surgery” 
(Batista procedure). The concept of surgical size re-
duction of the dilated left ventricle for preventing or 
reversing remodeling is similar to that used in ICM. 
However, the difference from the surgical treatment 
of ICM is that instead of the infarcted region, the 
remaining cardiac muscle with deteriorated func-
tion is removed.
 
Outcomes
 
After Batista’s report, additional tests were con-
ducted in Europe and the United States, and accord-
ing to a report published by Cleveland Clinic on a 
study conducted on New York Heart Association 
(NYHA) class III or IV heart transplant candidates 
with a left ventricular end-diastolic diameter > 70 
mm, the rate of patients who require heart trans-
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plantation and assisted circulation because of acute 
circulatory failure was as high as 16%, and the 
rates of mortality and avoidance of recurrent heart 
failure at 1 year and at 3 years were 49% and 26%, 
respectively, which were considered low (Franco-
Cereceda et al., 2001). Although the symptoms and 
left ventricular function certainly improved in some 
patients over time, such an outcome was difficult to 
predict preoperatively; therefore, this surgical tech-
nique was not performed in Europe and the United 
States. In Japan, because of the small number of 
heart transplant donors, the technique is performed 
as an alternative to heart transplantation in some 
institutions. Efforts aimed at improving outcomes 
continue and include the evaluation of local cardiac 
function before or during surgery, the resection of 
all regions showing poorest systolic contractions, 
rather than limiting the resection to only the poste-
rior wall (Suma and RESTORE Group, 2001), and 
myocardioplasty in which the myocardium is left in 
place and is superimposed instead of resected (over-
lapping method) (Matsui et al., 2004).
 
 
Cardiac transplantation
 
For more severe forms of heart failure in which 
no improvement is observed even after maximum 
medical treatment or after having been treated 
with the new surgical techniques described earlier, 
heart transplantation is the most effective method 
of treatment. One of the indications for heart trans-
plantation is a diagnosis with a 2-year survival rate 
of about 50%. Meanwhile, patients treated by heart 
transplantation have a 2-year survival rate of 80% 
and a 10-year survival rate of 50%. Even from the 
perspective of malignant diseases, a 2-year survival 
rate of 50% suggests that a disease has quite a poor 
prognosis. Of the currently available treatments, 
heart transplantation is the one that can be expected 
to ensure the highest survival rate for such patients. 
Currently, approximately 3,000 patients per year 
undergo cardiac transplantation all over the world. 
In Japan as well, cardiac transplantation was of-
ficially initiated in 1997 after the establishment of 
the Organ Transplant Law; however, because of 
various restrictions pertaining to organ donation 
from brain-dead patients, such as the strict appli-
cation of the law requiring the donor to provide a 
written document stating their intent to donate or-
gans before their death, very few people were able 
to receive heart transplants, and patients had to go 
through a long waiting period before undergoing 
cardiac transplantation. In response to that trend, 
the Revised Organ Transplant Law was enacted in 
2010. Since the revised law was enforced, organ 
donation from brain-dead patients has become pos-
sible upon consent from their families, even if the 
patients themselves did not clearly show an inten-
tion to donate their organs before their death. In 
addition, organ donation from brain-dead children 
less than 15 years of age has also become possible. 
Since the enforcement of the revised law, organ do-
nations from brain-dead patients have increased in 
number, and the number of cardiac transplantations 
performed per year has also increased, from 5 to 
10 in the past to approximately 50. However, due to 
the increasing number of registered patients waiting 
for heart transplants, the changes did not lead to a 
shortening of the transplant waiting period.
 Although cardiac transplantation is currently 
the most well-established therapeutic method for 
severe heart failure, it has also encountered vari-
ous problems. One of which is the need for organ 
donation from brain-dead patients; the other is 
lifetime immunosuppressive therapy in most cases. 
Immunosuppressive agents are often expensive and 
impose a heavy financial burden on patients. In ad-
dition, the side effects of immunosuppressive agents 
are associated with various problems, including ag-
gravation of arteriosclerosis and osteoporosis due 
to steroid use and an increase in carcinogenesis due 
to long-term suppression of immunocompetence. 
Therefore, efforts have been made to develop im-
munosuppressive drugs with fewer side effects. 
Given the problems associated with cardiac trans-
plantation, treatment outcomes could be better if 
therapeutic methods are developed that provide a 
better vital prognosis than that associated with heart 
transplantation or which ensure an improvement in 
53
Surgical treatment for heart failure
QOL in a manner that outweighs that due to heart 
transplantation. Under such circumstances, treat-
ments that use VADs have received attention.
 
 
Use of VADs
for the treatment of heart failure
The major VADs currently in use  
 
VADs, which began to be developed in the 1970s, 
have been used in clinical settings since the mid-
1990s as bridges in heart transplantation. Some 
VADs are extracorporeal, and the others are intra-
corporeal. Those that were used in the 1990s were 
all pulsatile pumps. Because the types of pumps 
that are implantable inside the abdominal wall or 
inside the abdominal cavity are excellent in terms 
of QOL for patients wearing them, implantable 
pulsatile pumps have been widely used. The pumps 
were known as the first generation of implantable 
devices. In the early 2000s, the first-generation 
devices were found to have limitations such as the 
fact that the implanted portion was large, infections 
developed easily, and the mechanical durability of 
the devices was problematic. Therefore, the second 
and third generations of artificial hearts were devel-
oped. These have been successfully used in clinical 
settings. The new generation of devices consists of 
continuous-flow pumps such as axial-flow pumps 
and centrifugal pumps that are miniaturized. Their 
durability has also improved. The second-generation 
devices have a rolling-contact bearing of the rotor, 
and the third-generation devices have further im-
proved durability and no longer have rolling-contact 
bearing. Previous reports have shown that because 
of the small size of the second-generation and third-
generation VADs, surgery is less invasive and com-
plications such as infection are less frequent (Frazier 
et al., 2004).
 
Pulsatile pumps
Pulsatile pumps, which are known as the first-gener-
ation VADs, are of 2 different types: the paracorpo-
real type and the implantable type. Compared to the 
paracorporeal VADs, implantable VADs generally 
have a blood pump implanted inside the body, such 
as in the abdominal region, and are therefore asso-
ciated with a smaller risk of infection. In addition, 
because they are also excellent with regard to pa-
tient QOL, they are believed to be more suitable for 
long-term assistance lasting several months or more. 
Currently, the VADs that are most commonly used 
in Japan are the paracorporeal pumps manufactured 
by Nipro Corporation (Osaka, Japan) (Fig. 1).
 When used for long-term assistance, paracor-
poreal pneumatically-driven VADs are associated 
with a poorer QOL than that allowed by the im-
plantable type. However, like implantable pumps, 
they are useful as a bridge to heart transplantation. 
They are particularly useful for patients with a small 
physique whose body surface area is less than 1.5 
m2, for pediatric patients, and for patients in need 
of bilateral ventricular assist system who, because 
of severe right heart failure, must be implanted with 
a VAD in the right ventricle in addition to that in 
the left ventricle. This is because the currently used 
implantable pumps have been designed to assist the 
left ventricle, and do not allow a second one to be 
implanted in the right ventricle. On the other hand, 
HeartMate (Thoratec) and Novacor (WorldHeart) 
are typical implantable pulsatile pumps (Fig. 2). 
Altogether, these 2 models have been used in more 
than 5000 cases worldwide; however, they have 
been rarely used since 2010 because continuous-
flow pumps were found to be better.
Continuous-flow pumps
Since the 1990s, active research and development 
has been done on the continuous-flow pumps such 
as implantable axial-flow pumps and centrifugal 
pumps. Their advantages include the fact that their 
size is smaller than those of conventional pulsa-
tile pumps, they cost less because of their simple 
structure, and there is no need for artificial heart 
valves. Altogether, MicroMed DeBakey, HeartMate 
II (Thoratec), and Jarvik 2000 (Jarvik Heart, New 
York, NY; Fig. 3) have been used in clinical settings 
in more than 2000 cases in Europe and the United 
States. There has been a particularly exponential 
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Fig. 2. Implantable pulsatile pumps. 
Two cannulas are connected to the left 
ventricle and asciendng aorta, respec-
tively. Pumps are sit either in the abdo-
minal wall or in the abdominal cavity. 
 
Left: Novacor (WorldHeart, Ottawa, 
Canada). 
Right: HeartMate I (Thoratec,  
Pleasanton, CA). 
Fig. 1. Nipro pneumatically-
driven paracorporeal pump. 
 
Left: pump is sit outside 
the body and connected 
to the console. The two 
cannulas penetrating 
the skin were connected 
to the left atrium and 
ascending aorta, respec-
tively. 
Right: a patient supported 
with Nipro pump. The 
patient is fully ambulat-
ed, but needs to go with 
the large consele next to 
him.
Fig. 3. Jarvik 2000, an implantable 
continuous flow pump. 
 
Left: Jarvik 2000 is shown on the palm. 
Note that the size is much smaller 
than those of the implantable pulsa-
tile pumps. 
Right: chest X-ray of a patient supported 
with Jarvik 
2000. The 
pump itself 
is sit in the 
left ventricu-
lar cavity.
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increase in the use of the HeartMate II, which has 
almost replaced the first-generation pulsatile pumps.
 In Japan as well, 2 models of implantable cen-
trifugal pumps, namely EVAHEART (Sun Medi-
cal, Suwa, Japan) and DuraHeart (Terumo, Tokyo, 
Japan), received approval for manufacture and sale 
in January 2011, and have been approved for insur-
ance reimbursement since April 2011. HeartMate II 
(Thoratec) and Jarvik 2000 (Jarvik Heart) are also 
pending approval.
New purposes of employing VADs “bridge 
to recovery”
 
In 1990, when the use of VADs as a bridge to-
wards heart transplantation became popular, it 
was believed that a VAD was installed in case of 
severe end-stage heart failure due to cardiomyopa-
thy, which is a basically progressive disease, and 
therefore, withdrawal from the use of VADs was 
considered extremely difficult. However, in 1997, 
the Berlin Heart Institute reported that 17 patients 
with idiopathic DCM could withdraw from VADs, 
and the phenomenon attracted attention (Müller et 
al., 1997). A normalization of neurohumoral fac-
tors, an improvement of calcium handling in myo-
cardial cells, and an increase in the number of beta 
adrenergic receptors are thought to occur while the 
cardiovascular circulation is assisted and the load 
on the heart is reduced by VADs. In Japan, where 
brain-dead donors are difficult to find, the “bridge 
to recovery” strategy is much more important than 
it is in Western countries, and its availability to all 
patients wearing VADs should be pursued. For all 
patients who undergo placement of a VAD in our 
institution, medical treatment of heart failure, con-
sisting of the administration of medications such as 
beta-blockers and angiotensin-converting enzyme 
inhibitors, is initiated after the device has been put 
in place, as soon as the patient is capable of ingest-
ing food and liquid orally. Recently, there has been 
a focus on strategies that aim at withdrawal from 
VADs by using methods that actively contribute to 
the recovery of left ventricular function in patients 
wearing the device; therefore, pharmacotherapy 
and ventricular resynchronization, combined with 
surgical treatments such as mitral valvuloplasty, 
left ventricular reduction surgery, and regenerative 
treatments such as cell transplantation and gene 
therapy, have been reported to be useful (Nishimura 
et al., 2005). However, it is currently difficult to pre-
dict patients in which cardiac functional recovery is 
possible. In addition, future studies are expected to 
solve the issue of predicting or preventing the recur-
rence of heart failure after withdrawal from VADs 
and of evaluating the extent of recovery of cardiac 
function in patients wearing a VAD.
Conclusion: Although there have been remarkable 
developments in medical treatment for heart failure, 
surgery still plays an important role in its treatment, 
particularly in severe heart failure cases. In the fu-
ture, combinations of a wider variety of therapeutic 
methods could be promising in improving treatment 
outcomes in severe heart failure.
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